相关实验视频

Updated: Jan 8, 2026

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

分析MRPL23蛋白表达及其在前列腺癌发病过程中的作用

Edyta Podemska¹, Damian Łukasik¹, Jędrzej Borowczak^2,3

¹Department of Clinical Pathomorphology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-094 Bydgoszcz, Poland.

|December 20, 2025

概括

线粒体核糖体蛋白L23 (MRPL23) 在前列腺癌 (PCa) 组织中升高,特别是在转移中. 高MRPL23表达预测生存和复发不佳,建议它作为预后生物标志物和潜在的治疗标.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症研究癌症研究

背景情况:

前列腺癌 (PCa) 由于其异质性和缺乏可靠的预后生物标志物而构成重大临床挑战.
线粒体核糖体蛋白L23 (MRPL23) 与癌症进展有关,但其在PCa中的具体作用尚不清楚.

研究的目的:

研究前列腺癌组织中MRPL23的表达及其与临床病理特征和患者存活率的相关性.
评估MRPL23作为前列腺癌潜在的预后生物标志物和治疗点.

主要方法:

免疫组织化学被用来评估MRPL23表达在67名PCa患者的甲固定,嵌 (FFPE) 组织样本中.
用卡普兰-梅尔曲线和考克斯比例危险模型分析了临床病理学数据和生存结果.
使用TCGA数据来确认MRPL23mRNA水平及其与无病存活率的关联.

主要成果:

在PCa组织中,MRPL23的表达显著高于正常上皮质,在淋巴结转移中最高水平.
高MRPL23表达与较短的整体存活率相关,是独立的预后因素 (HR 3.99).
TCGA分析证实了前列腺腺癌中MRPL23mRNA的升高,并预测了较短的无病生存期 (日志排名P = .01).

结论:

MRPL23是前列腺癌的潜在预后生物标志物,与瘤的攻击性行为和不良结果有关.
转移性组织中MRPL23表达的升高表明它在疾病进展中的作用.
MRPL23可能成为晚期前列腺癌的治疗点.

关键词:

在 MRPL23 课程中,免疫组织化学免疫组织化学患者的生存率患者的生存率预后生物标志物预后生物标志物前列腺癌是前列腺癌.

更多相关视频

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

Published on: May 16, 2012

Laser-capture Microdissection of Human Prostatic Epithelium for RNA Analysis

Laser-capture Microdissection of Human Prostatic Epithelium for RNA Analysis

Published on: November 26, 2015

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...